OTCMKTS:BNOEF Bionomics (BNOEF) Stock Price, News & Analysis $0.0034 0.00 (-43.33%) As of 09/19/2023 Add Compare Share Share Stock Analysis Stock Analysis About Bionomics Stock (OTCMKTS:BNOEF) Get Bionomics alerts:Sign Up Key Stats Today's Range$0.0034▼$0.003450-Day Range N/A52-Week Range$0.00▼$0.06Volume22,900 shsAverage Volume140,299 shsMarket Capitalization$4.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Bionomics Limited is an Australian clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. The company’s research has centered on therapies for conditions involving anxiety, trauma, cognition and related neurological processes. Bionomics’ primary investigational product has been BNC210, an orally administered, small-molecule modulator of the alpha-7 nicotinic acetylcholine receptor. The program has been evaluated in clinical studies for disorders including post-traumatic stress disorder and social anxiety disorder. BNC210 is an experimental medicine and has not been approved for commercial use. Founded in 1999 and headquartered in Adelaide, South Australia, Bionomics has conducted drug discovery and clinical development activities through collaborations and trials involving international research and healthcare organizations. The company’s work has historically focused on advancing neuroscience programs toward potential treatments for patients with significant unmet medical needs.AI Generated. May Contain Errors. Read More Receive BNOEF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BNOEF Stock News HeadlinesNeuphoria Therapeutics More Than Doubles After Bionomics Re-DomiciliationDecember 25, 2024 | marketwatch.comBionomics announces Australia Supreme Court approves re-domiciliationDecember 17, 2024 | markets.businessinsider.com“The crisis that’s emerging now is just the tip of the iceberg,” says Dr. Martin D. Weiss, who has made shocking and accurate predictions for 55 yearsDr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehman Brothers, is warning of a developing financial crisis. The New York Times has credited him as among the first to see the dangers ahead, and Forbes dubbed him Mr. Independence. He says this emerging situation could trigger a chain reaction across banks and markets. Watch his free video breakdown and see the five steps he outlines for investors.October 16 at 1:00 AM | Weiss Ratings (Ad)Bionomics Announces Supreme Court of New South Wales Approves Bionomics’ Re-DomiciliationDecember 16, 2024 | markets.businessinsider.comBionomics publishes resuls from Phase 2 ATTUNE study of BNC210December 9, 2024 | markets.businessinsider.comBionomics to Present at the 2024 CNS SummitNovember 7, 2024 | markets.businessinsider.comWhy Bionomics (BNOX) Stock Is Up 100% TodayNovember 5, 2024 | benzinga.comBionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology ProgramNovember 4, 2024 | markets.businessinsider.comSee More Headlines BNOEF Stock Analysis - Frequently Asked Questions How have BNOEF shares performed this year? Bionomics' stock was trading at $0.0034 at the start of the year. Since then, BNOEF shares have increased by 0.0% and is now trading at $0.0034. Company Calendar Today10/16/2026Fiscal Year End6/30/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:BNOEF CIK1191070 Webwww.bionomics.com.au Phone(188) 150-7400FaxN/AEmployeesN/AYear Founded1996Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares1,309,557,000Free FloatN/AMarket Cap$4.45 million OptionableNot Optionable Beta1.86 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (OTCMKTS:BNOEF) was last updated on 9/19/2023 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredSpaceX minted 4400 millionaires in a single daySpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bionomics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bionomics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
